Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas

Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.